| Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
|---|---|---|---|---|---|
Gross Sales | 2,125.63 | 2,318.77 | 2,171.39 | 2,341.63 | 2,170.29 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,125.63 | 2,318.77 | 2,171.39 | 2,341.63 | 2,170.29 |
Other Operating Income | 20.85 | 12.6 | 3.61 | 0 | 0 |
Other Income | 5.32 | 2.52 | 1.88 | 4.32 | 9.46 |
Total Income | 2,151.8 | 2,333.89 | 2,176.88 | 2,345.95 | 2,179.75 |
Total Expenditure | 1,683.9 | 1,825.18 | 1,825.21 | 1,882.22 | 1,715.88 |
PBIDT | 467.91 | 508.71 | 351.68 | 463.73 | 463.87 |
Interest | 52.69 | 57.4 | 48.42 | 35.77 | 20.16 |
PBDT | 415.22 | 451.31 | 303.26 | 427.96 | 443.71 |
Depreciation | 105.39 | 105.57 | 101.76 | 97.07 | 87.43 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 84.08 | 103.36 | 61.87 | 97.97 | 79.21 |
Deferred Tax | -6.14 | -12.92 | -10.39 | -11.02 | 4.41 |
Reported Profit After Tax | 231.88 | 255.3 | 150.01 | 243.93 | 272.66 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 231.88 | 255.3 | 150.01 | 243.93 | 272.66 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 231.88 | 255.3 | 150.01 | 243.93 | 272.66 |
EPS (Unit Curr.) | 9.57 | 10.53 | 6.2 | 10.08 | 10.99 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 24.24 | 24.24 | 24.24 | 24.2 | 24.83 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 22.01 | 21.93 | 16.19 | 19.8 | 21.37 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 10.9 | 11.01 | 6.9 | 10.41 | 12.56 |
The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.
Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.
The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.
Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).
The USFDA has also noted a repeat observation from the company's January 2023 inspection.
Glycopyrrolate Oral Solution is an anticholinergic medication used to treat pediatric patients aged 3 to 16 years with neurological conditions that cause drooling.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
